Raising the Stakes On Value-Based Pricing

[...]pharmaceutical manufacturers will increasingly need to demonstrate value to global payers and health technology assessment (HTA) bodies as a prerequisite for premium prices and/or significant price increases. Together with other conventional pharmaceutical company offerings (e.g., disease management program support and caredelivery "hub" services), these arrangements have the potential to change the dialogue between manufacturers and payers, from price to value. [...]the industry consistently provides solutions to reinforce the value of new therapies, consumers, payers, and politicians will continue to focus on the cost side of the equation, applying price caps and arbitrary access "austerity" measures that do not recognize or reward innovation.